Providing the EAP for the GVHD cohort in the absence of effective FDA alternatives has proven the worth of Ryoncil to patients, their families and the medical community. However having it as a fail safe to the demographic has ultimately reduced the urgency factor for the FDA. There has been no rush leading up to the two CRL’s because assurances must have been made that the EAP would continue regardless of the FDA’s decision. Hopefully Si has similar assurances this time round re approval.
Providing the EAP for the GVHD cohort in the absence of...
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |